

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

3015/6/US

SERIAL NO.

10/021780

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Anantanarayan et al.

FILING DATE

12/07/01

GROUP

1626

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------|---------|-----------------|-------|----------|-------------------------------|
| Yo | 1 | 3,254,093 | 05/1966 | Huisgen et al. | 260 | 295 | |
| | 2 | 3,984,431 | 10/1976 | Gueremy et al. | 280 | 310 | |
| | 3 | 4,000,281 | 12/1976 | Beiler et al. | 424 | 283 | |
| | 4 | 5,051,518 | 09/1991 | Murray et al. | 548 | 373 | |
| | 5 | 5,134,142 | 07/1992 | Matsuoka et al. | 514 | 255 | |
| | 6 | 5,559,137 | 09/1996 | Adams et al. | 514 | 341 | |
| | 7 | 5,486,534 | 01/1996 | Lee et al. | 514 | 406 | |
| | 8 | 5,589,439 | 12/1996 | Goto et al. | 504 | 261 | |
| | 9 | 5,658,903 | 08/1997 | Adams et al. | 514 | 235.8 | |
| | 10 | 5,739,143 | 04/1998 | Adams et al. | 514 | 275 | |
| | 11 | 5,756,529 | 05/1998 | Isakson et al. | 514 | 406 | |
| | 12 | 5,972,972 | 10/1999 | Mihelich et al. | 514 | 341 | |
| ✓ | 13 | 5,998,425 | 12/1999 | Adams et al. | 514 | 275 | |

FOREIGN PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----------------------|----|----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| Yo | 14 | WO 83/00330 | 02/1983 | PCT | | | | |
| | 15 | WO 92/19615 | 11/1992 | PCT | | | | |
| | 16 | WO 95/06036 | 03/1995 | PCT | | | | |
| | 17 | WO 95/22545 A1 | 08/1995 | PCT | | | | |
| ✓ | 18 | WO 96/03385 A1 | 02/1996 | PCT | | | | |

EXAMINER

T. A. Solola

DATE CONSIDERED

6-4-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

3015/6/US

SERIAL NO.

10/021780

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Anantanarayan et al.

FILING DATE

12/07/01

GROUP

1626

| | | | | | | | | | |
|----|----|---------------------|---------|-----|--|--|--|--|--|
| 40 | 19 | WO 96/21452 A1 | 07/1996 | PCT | | | | | |
| | 20 | WO 96/21654 A1 | 07/1996 | PCT | | | | | |
| | 21 | WO 96/40143 A1 | 12/1996 | PCT | | | | | |
| | 22 | WO 97/01551 | 01/1997 | PCT | | | | | |
| | 23 | WO 97/23479 A1 | 07/1997 | PCT | | | | | |
| | 24 | WO 97/25046 A1 | 07/1997 | PCT | | | | | |
| | 25 | WO 97/25047 A1 | 07/1997 | PCT | | | | | |
| | 26 | WO 97/25048 A1 | 07/1997 | PCT | | | | | |
| | 27 | WO 97/32583 A1 | 09/1997 | PCT | | | | | |
| | 28 | WO 97/35855 A1 | 10/1997 | PCT | | | | | |
| | 29 | WO 97/35856 A1 | 10/1997 | PCT | | | | | |
| | 30 | WO 97/47618 A1 | 12/1997 | PCT | | | | | |
| | 31 | WO 98/07425 A1 | 02/1998 | PCT | | | | | |
| | 32 | WO 98/16230 A1 | 04/1998 | PCT | | | | | |
| | 33 | WO 98/25619 A1 | 06/1998 | PCT | | | | | |
| | 34 | WO 98/52937 A2 & A3 | 11/1998 | PCT | | | | | |
| | 35 | WO 98/52940 A1 | 11/1998 | PCT | | | | | |
| | 36 | WO 98/52941 A1 | 11/1998 | PCT | | | | | |
| | 37 | WO 98/57968 A1 | 12/1998 | PCT | | | | | |
| | 38 | WO 99/01130 A1 | 01/1999 | PCT | | | | | |
| | 39 | WO 99/01131 A1 | 01/1999 | PCT | | | | | |
| | 40 | WO 99/01136 A1 | 01/1999 | PCT | | | | | |

EXAMINER

T. A. Solola

DATE CONSIDERED

6-4-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | | | | |
|---|----|----------------|---------|---------|--|--|-----------------------------------|--|-------------------------|---|
| FORM PTO-1449 (REV. 7-80) | | | | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 3015/6/US | | SERIAL NO. 10/021780 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | | | | APPLICANT Anantanarayan et al. | | | |
| | | | | | | | FILING DATE 12/07/01 | | GROUP 1626 | |
| | | | | | | | | | | |
| 40 | 41 | WO 99/01452 A1 | 01/1999 | PCT | | | | | | |
| | 42 | WO 99/17776 A1 | 04/1999 | PCT | | | | | | |
| | 43 | WO 99/32121 A1 | 07/1999 | PCT | | | | | | |
| | 44 | WO 99/61426 A1 | 12/1999 | PCT | | | | | | |
| | 45 | 0 115 640 A2 | 12/1983 | EPO | | | | | | |
| | 46 | 0 418 845 A1 | 03/1991 | EPO | | | | | | |
| | 47 | 0 515 041 A2 | 11/1992 | EPO | | | | | | |
| | 48 | 0 531 901 A2 | 03/1993 | EPO | | | | | | |
| | 49 | 4-145081 | 05/1992 | JAPAN | | | | | | X |
| | 50 | 5-17470 | 01/1993 | JAPAN | | | | | | X |
| | 51 | 5-345772 | 12/1993 | JAPAN | | | | | | X |
| | 52 | 8-183787 | 07/1996 | JAPAN | | | | | | X |
| | 53 | WO 94/19350 | 09/1994 | PCT | | | | | | |
| | 54 | WO 95/31451 | 11/1995 | PCT | | | | | | |
| | 55 | 0 846 686 A1 | 06/1998 | EPO | | | | | | |
| | 56 | 0 846 687 A1 | 06/1998 | EPO | | | | | | |
| ✓ | 57 | DD 295 374 A5 | 10/1991 | GERMANY | | | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|----|---|
| 40 | 58 | Boehm, J.C. et al., "New Inhibitors Of p38 Kinase", Exp. Opin. Ther. Patents, Vol. 10(1), pp. 25-36, (2000), ✓ |
| | 59 | Laszlo, S.E. et al., "Pyrroles And Other Heterocycles As Inhibitors Of p38 Kinase", <i>Bioorganic & Medicinal Chemistry Letters</i> 8, pp. 2689-2694, 1998. ✓ |
| ✓ | 60 | Dannhardt G. et al., "ω-Aminopropyl-pyrazole durch Ringtransformation von Enaminonen der Pyrrolidinreihe", Arch. Pharm., Vol. 321, No. 1, pp. 17-19, 1988. ✓ |

EXAMINER

T.A. Solok

DATE CONSIDERED

6/4/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|----|----|---|
| Yo | 61 | Zheng-Nian Huang, "Synthesis and Biological Activities of 1-(substituted pyrazol-4-yl)-1,2,4-triazoles", <i>Chemical Abstracts</i> , Volume 124, No. 23, Abstract No. 317062d, 1996. ✓ |
| | 62 | Chemical Abstracts, 13 th Collective Chemical Substance Index 1992-1996, Book 51, pp. 546-550. ✓ |
| | 63 | Zhengming, Li et al., "Syntheses of Di-heterocyclic Compounds; Pyrazolylimidazoles And Isoxazolylimadazoles", <i>Heteroatom. Chem.</i> , Vol. 9, No. 3, pp. 317-320, 1996. ✓ |
| | 64 | Zheng-Nian Huang, "The Reaction Of α -OXO- α -Triazolyketene Dithioacetal With Amines, Hydrazine And Guanidine", <i>Chinese Chemical Letters</i> , Vol. 5, No. 1, pp. 31-34, 1994. ✓ |
| | 65 | Popova, A.N. et al., "Synthesis Of 4-(Pyrazol-4-yl)-Substituted Salts Of Pyryllum And Pyridines", <i>Chemical Abstracts</i> , Vol. 098, No. 1, January 3, 1983, Abstract No. 004498. ✓ |
| | 66 | Bauer, V.J. et al., "4-3(5)-Pyrazolyl Pyridinium Salts. A New Class Of Hypoglycemic Agents", <i>J. Med. Chem.</i> , Vol. 11; pp. 981-4, (September 1968). ✓ |
| | 67 | Cativiela, C. et al., "On the Synthesis Of 3(5)-(Carbomethoxy)-4-hetarylpyrazoles", <i>J. Heterocycl. Chem.</i> , Vol. 25; pp. 851-5, (May-June 1988). ✓ |
| | 68 | Fischer, U. et al., "1,3-Dipolar Additions To 7-Methylthieno [2,3-c]pyridine 1,1-dioxide", <i>Helv. Chim. Acta</i> ; Vol. 63(6), No. 180, pp. 1719-27, (1980). ✓ |
| | 69 | September 24, 1998 PCT International Search Report (PCT/US98/10436) |
| | 70 | Badger, Alison M. et al., "Disease-Modifying Activity Of SB 242235, A Selective Inhibitor Of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis", <i>Arthritis & Rheumatism</i> , Vol. 43, No. 1, pp. 175-183, 2000. ✓ |
| | 71 | Henry, James R., "p38 Mitogen-Activated Protein Kinase As A Target For Drug Discovery", <i>Drugs of the Future</i> , Vol. 24, pp. 1345-1354, 1999. ✓ |
| | 72 | Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention Cytokine-Mediated Diseases", <i>Current Medicinal Chemistry</i> , Issue 6, pp. 807-823, 1999. ✓ |
| | 73 | Liverton, N.J. et al., "Design And Synthesis Of Potent, Selective, And Orally Bioavailable Tetrasubstituted Imidazole Inhibitors Of p38 Kinase Mitogen-Activated Protein Kinase", <i>J. Med. Chem.</i> , Vol. 42, pp. 2180-2190, 1999. ✓ |
| | 74 | Adams, J.L. et al., "Pyrimidinylimidazole Inhibitors Of CSBP/p38 Kinase Demonstrating Decreased Inhibition Of Hepatic Cytochrome p450 Enzymes", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 8, pp. 3111-3116, 1998. ✓ |
| | 75 | Gallagher, T.F., "Regulation Of Stress-Induced Cytokine Production By Pyridinylimidazoles; Inhibition Of CSBP Kinase", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 5, pp. 49-64, 1997. ✓ |
| | 76 | Hanson, G.J., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", <i>Exp. Opin. Ther. Patents</i> , Vol. 7, pp. 729-733, 1997. ✓ |
| | 77 | Moerck R.E. et al., "Pyrazole Addition To Δ^1 -Azirines. Structure of Purported 2:1 Adducts of Δ^1 -Azirines With sym-Tetrazines", <i>J.Chem. Soc., Chem. Commun.</i> , No. 19, pp. 782-783 (1974). ✓ |

EXAMINER

T. A. Solala

DATE CONSIDERED

6-4-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|-----------------------------|------------|
| FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 1 | ATTORNEY DOCKET NO. | SERIAL NO. |
| | 3015/6/US (6794-000032/COA) | 10/021,780 |
| | APPLICANT | |
| | Anantanarayan et al. | |
| | FILING DATE | GROUP |
| December 7, 2001 | 1626 | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|---------------------|---|---------|---------------------------------|-----------------|------------------------------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date |
| 78. | X | U.S. Patent Application No. 09/196,623 (co-pending grandparent application; examined and allowed by Examiner Taofiq Solola) | | Anantanarayan et al. | | 11/20/1998 |
| 79. | * | U.S. Patent Application No. 09/513,351 (co-pending parent application; examined and allowed by Examiner Taofiq Solola) | | Anantanarayan et al. | | 02/24/2000 |
| 80. | Yo | 6,423,713 (offspring of Ref. No. 78; examined by Examiner Taofiq Solola) | 07/2002 | Anantanarayan et al. | 514/235.8 | 07/31/2001 |
| 81. | * | U.S. Patent Application No. 10/114,297 (co-pending offspring of Ref. Nos. 78 and 80; being examined by Examiner Taofiq Solola) | | Anantanarayan et al. | | 04/02/2002 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|---------------------|--|-----------|---------|-----------------|--------------------|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes No |
| 82. | Yo | 8-183787 (English machine translation) | 07/1996 ✓ | JAPAN | | X |

* Application: recent valid prior arts. Patent Nos should be cited where applicable.

| | |
|----------------------|-------------------------|
| Examiner: T-A-Solola | Date Considered: 6-4-03 |
|----------------------|-------------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.